Fax: (713) 563-2331
Article first published online: 22 MAR 2011
Copyright © 2011 American Cancer Society
Volume 117, Issue 20, pages 4707–4713, 15 October 2011
How to Cite
Chang, J. Y., Komaki, R., Lu, C., Wen, H. Y., Allen, P. K., Tsao, A., Gillin, M., Mohan, R. and Cox, J. D. (2011), Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer, 117: 4707–4713. doi: 10.1002/cncr.26080
Portions of this work were presented at the 2009 annual meeting of the American Society of Radiation Oncology, Chicago, Illinois, November 1-5, 2009 and published in abstract form (Int J Radiat Oncol Biol Phys. 2009;75:S446).
We thank the Thoracic Radiation Oncology and Proton Therapy Center teams at The University of Texas MD Anderson Cancer Center for their help and support and Ms. Christine Wogan of the Division of Radiation Oncology at The University of Texas MD Anderson Cancer Center for editorial assistance.
- Issue published online: 5 OCT 2011
- Article first published online: 22 MAR 2011
- Manuscript Accepted: 21 JAN 2011
- Manuscript Revised: 18 JAN 2011
- Manuscript Received: 15 DEC 2010
- proton therapy;
- concurrent chemotherapy;
- nonsmall cell lung cancer;
- patterns of failure;
The authors sought to improve the toxicity of conventional concurrent chemoradiation therapy for stage III nonsmall cell lung cancer (NSCLC) by using proton-beam therapy to escalate the radiation dose to the tumor. They report early results of a phase 2 study of high-dose proton therapy and concurrent chemotherapy in terms of toxicity, failure patterns, and survival.
Forty-four patients with stage III NSCLC were treated with 74 grays (radiobiologic equivalent) proton therapy with weekly carboplatin (area under the curve, 2 U) and paclitaxel (50 mg/m2). Disease was staged with positron emission tomography/computed tomography (CT), and treatments were simulated with 4-dimensional (4D) CT to account for tumor motion. Protons were delivered as passively scattered beams, and treatment simulation was repeated during the treatment process to determine the need for adaptive replanning.
Median follow-up time was 19.7 months (range, 6.1-44.4 months), and median overall survival time was 29.4 months. No patient experienced grade 4 or 5 proton-related adverse events. The most common nonhematologic grade 3 toxicities were dermatitis (n = 5), esophagitis (n = 5), and pneumonitis (n = 1). Nine (20.5%) patients experienced local disease recurrence, but only 4 (9.1%) had isolated local failure. Four (9.1%) patients had regional lymph node recurrence, but only 1 (2.3%) had isolated regional recurrence. Nineteen (43.2%) patients developed distant metastasis. The overall survival and progression-free survival rates were 86% and 63% at 1 year.
Concurrent high-dose proton therapy and chemotherapy are well tolerated, and the median survival time of 29.4 months is encouraging for unresectable stage III NSCLC. Cancer 2011;. © 2011 American Cancer Society